Review of the frequency stabilization of TEA CO2 laser oscillators

Most applications of TEA CO2 lasers in heterodyne radar systems require that the transmitter has a high degree of frequency stability. This ensures good Doppler resolution and maximizes receiver sensitivity. However, the environment within the device is far from benign with fast acoustic and electrical transients being present. Consequently the phenomena which govern the frequency stability of pulsed lasers are quite different from those operative in their CW counterparts. This review concentrates on the mechanisms of chirping within the output pulse; pulse to pulse frequency drift may be eliminated by frequency measurement and correction on successive pulses. It emerges that good stability hinges on correct cavity design. The energy-dependent laser-induced frequency sweep falls dramatically as mode diameter is increased. Thus, it is necessary to construct resonators with good selectivity for single mode operation while having a large spot size

Pulsed-discharge carbon dioxide lasers

The purpose is to attempt a general introduction to pulsed carbon dioxide lasers of the kind used or proposed for laser radar applications. Laser physics is an excellent example of a cross-disciplinary topic, and the molecular spectroscopy, energy transfer, and plasma kinetics of the devices are explored. The concept of stimulated emission and population inversions is introduced, leading on to the molecular spectroscopy of the CO2 molecule. This is followed by a consideration of electron-impact pumping, and the pertinent energy transfer and relaxation processes which go on. Since the devices are plasma pumped, it is necessary to introduce a complex subject, but this is restricted to appropriate physics of glow discharges. Examples of representative devices are shown. The implications of the foregoing to plasma chemistry and gas life are discussed

Dissociation phenomena in electron-beam sustained carbon dioxide lasers

A number of applications are emerging requiring efficient, long pulse, long-life sealed CO2 lasers. Examples include the proposed NASA and ESA wind lidars. Electron-beam sustained discharge devices are strong contenders. Unlike self-sustained discharges, e-beam sustenance readily provides efficient performance from large volume discharges and offers pulse lengths well in excess of the microsecond or so generally associated with self-sustained devices. In the case of the e-beam sustained laser, since the plasma is externally maintained and operated at electric field strengths less than that associated with the glow to arc transition, the discharges can be run even in the presence of strongly attacking species such as O2. Build up of large levels of attacking contaminants is nevertheless undesirable as their presence reduces the current drawn by the plasma and thus the pumping rate to the upper laser level. The impedance rise leads to a mismatch of the pulse forming network with a consequent loss of control over energy deposition, operating E/N, and gain. Clearly CO2 dissociation rates, the influence of dissociation products on the discharge and gain, and tolerance of the discharge to these products need to be determined. This information can then be used to assess co-oxidation catalyst requirements for sealed operation

Closed-Cycle, Frequency-Stable CO2 Laser Technology

These proceedings contain a collection of papers and comments presented at a workshop on technology associated with long-duration closed-cycle operation of frequency-stable, pulsed carbon dioxide lasers. This workshop was held at the NASA Langley Research Center June 10 to 12, 1986. The workshop, jointly sponsored by the National Aeronautics and Space Administration (NASA) and the Royal Signals and Radar Establishment (RSRE), was attended by 63 engineers and scientists from the United States and the United Kingdom. During the 2 1/2 days of the workshop, a number of issues relating to obtaining frequency-stable operation and to the catalytic control of laser gas chemistry were discussed, and specific recommendations concerning future activities were drafted

Photoacoustic spectroscopy for remote detection of liquid contamination

The remote detection and identification of liquid chemical contamination is a difficult problem for which no satisfactory solution has yet been found. We have investigated a new technique, pulsed indirect photoacoustic spectroscopy (PIPAS), and made an assessment of its potential for operation at stand-off ranges of order 10m. The method involves optical excitation of the liquid surface with a pulsed laser operating in the 9-11μm region. Pulse lengths are of order 3μs, with energy ∼300μJ and repetition rates ∼200Hz. Rapid heating of the liquid by the laser pulse produces acoustic emission at the surface, and this is detected by a sensitive directional microphone to increase the signal-to-noise ratio and reduce background clutter. The acoustic pulse strength is related to the liquid's absorption coefficient at the laser wavelength; tuning allows spectroscopic investigation and a means of chemical identification. Maximum coverage rates have been examined, and further experiments have examined the specificity of the technique, allowing a preliminary assessment of false-alarm and missed-signal rates. The practical aspects of applying the technique in a field environment have been assessed

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Pulsed Indirect Photoacoustic Spectroscopy: Application To Remote Detection Of Condensed Phases

The technique of pulsed indirect photoacoustic spectroscopy is applied to the examination of free liquid surfaces, and the prospects are assessed for remote detection and identification of chemical species in a field environment. A CO2 laser (tunable within the 9-11-μm region) provides pulsed excitation for a variety of sample types; the resulting photoacoustic pulses are detected at ranges of the order of a few centimeters. The phenomenon is investigated as a funtion of parameters such as temperature, sample depth, laser-pulse energy, pulse length, and beam diameter. The results are in good agreement with a theoretical model that assumes the mechanism to be expansion of air resulting from heat conduction from the laser-heated surface of the sample under investigation. Signal and noise processing issues are discussed briefly, and the possible extension of the technique to ranges of the order of 10 m is assessed. © 2000 Optical Society of America